Microfluidic Lung

描述（由申请人提供）：我们建议开发一种新的微流体方法，以实现真正长期可植入的人工肺。膜氧化已经取得了相当大的进步，包括我们自己之前的工作，创造了一个中空纤维膜阵列，在与室内空气的气体交换中比自然肺更有效。尽管取得了这些进步，但潜在的纤维技术对血液的表面积很大，导致膜污染和血液活化，这增加了血凝块的机会，通常需要抗凝治疗。我们的新解决方案结合了之前与空气进行气体交换的工作，但利用微流体技术以无膜的方式与血液进行气体交换。在本提案中，我们介绍了我们之前的工作，包括我们对设备设计和效率的初步分析。在第一阶段结束时，我们将证明我们的方法的可行性，并准备一个综合人工肺设计的详细图纸，我们将在第二阶段进一步发展并在动物研究中进行测试。Infoscitex完全致力于实现完全可植入人工肺的最终目标，并凭借该技术和并行开发的急性支持设备，在呼吸辅助设备领域产生相当大的影响。公共卫生相关性：在临床医学中使用人工肺来代替天然肺的气体交换功能的概念可以追溯到1954年心肺机的发展。大多数血气交换装置利用膜来进行气体交换，这会损害血液并导致危险的血凝块。最近，一些科学家探索了直接向血液中添加高氧液体，将液体从插入点移到下游。虽然对血液的损害较小，但这些系统从血液中去除二氧化碳的手段有限，不能用于慢性疾病。我们的系统利用了这两种方法的最佳概念，并建立在我们之前的工作基础上，开发了一种与血液无膜的界面，用于在血液和室内空气之间交换氧气和二氧化碳。我们的最终目标是开发一种完全可植入的用于慢性护理的人工肺，尽管我们的技术可以用于实现这一最终目标的其他平行设备。

DESCRIPTION (provided by applicant): We propose to develop a novel microfluidic approach that will enable the realization of a truly long-term implantable artificial lung. There have been considerable advances in membrane oxygenation, including our own previous work in creating a hollow fiber membrane array that is more efficient than natural lungs at gas exchange with room air. Despite these advances, the underlying fiber technology presents a large surface area to blood, causing fouling of the membrane and activation of the blood, which increases the chance of blood clots and often necessitates the need for anticoagulation therapy. Our novel solution incorporates the previous work to perform gas exchange with air but utilizes microfluidic technology to perform gas exchange with blood in a membrane-free manner. In this proposal we present our previous work towards this development including our initial analysis of the device design and efficiency. By the end of Phase I we will have demonstrated the feasibility of our approach and prepared detailed drawings of an integrated artificial lung design that we will further develop in Phase II and test in animal studies. Infoscitex is fully committed to realizing our end goal of a fully implantable artificial lung and stands to make a considerable impact in the field of respiratory assist devices with this technology and acute support devices developed in parallel. PUBLIC HEALTH RELEVANCE: The concept of using an artificial lung in clinical medicine to take over the gas exchange function of the native lung dates to the development of the heart-lung machine in 1954. Most blood gas exchange devices utilize membranes to perform the gas exchange, which damages the blood and can cause dangerous blood clots. More recently, some scientists have explored adding a highly oxygenated liquid directly into the blood, removing the liquid downstream from the insertion point. While less damaging to the blood, these systems have limited means of removing carbon dioxide from blood and cannot be used in a chronic condition. Our system utilizes the best of the concepts from these two approaches and builds on our previous work to develop a membraneless interface to the blood for exchanging both oxygen and carbon dioxide between blood and room air. Our final end goal is to develop a completely implantable artificial lung for chronic care, although our technology can be used for other parallel devices along the way to this end goal.